Evaluation of Current Practice of Antibiotic Use and Clinical Outcomes of Community-Acquired Pneumonia Patients with Type 2 Diabetes Mellitus in Indonesia
Abstract
Impaired immunity in diabetes mellitus (DM) causes reduced lung function, which increases the incidence of various types of infections, including community-acquired pneumonia (CAP). The main principle of CAP therapy is the administration of antibiotics. This study aims to assess the appropriate use of antibiotics according to existing clinical practice guidelines using the Gyssen algorithm, and to determine its effect on clinical outcomest in hospitalized patients. It is an observational study with a retrospective cohort design and total sampling technique. The research was conducted at Dr. Cipto Mangunkusumo Hospital Jakarta, with the research subjects being 98 hospitalized CAP patients with type 2 DM (T2DM) over the period January 2018 - December 2019. The collection of data on patient characteristics and clinical outcomes was made through patient medical records. 28.6% of the subjects were in the severe category of CAP. The results of the evaluation using the Gyssen algorithm showed that 59.2% of the subjects receive the appropriate antibiotics, while 40.8% receive non appropriate antibiotics. The clinical outcomes in the group receiving appropriate antibiotics (70.7%) was significantly higher than the non-appropriate group (42.5%). The results of the multivariate analysis show that the group receiving appropriate antibiotics experienced 2.7 times greater clinical outcomes (RR 2.683, 95% CI: 1.102-6.592), after controlling for the degree of CAP and the onset of antibiotic administration. The use of appropriate antibiotics in CAP patients with T2DM significantly enhanced clinical outcomes.
References
Bhambar, S., Deore, P., Rathod, R., & Smit, J. Pneumonia in Diabetics: Clinico- Bacteriological Profil and Outcome. International Journal of medical and health Research. 2017: 62-66.
Casqueiro, J., Casqueiro, J., & Alves, C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinology and Metabolism. 2012: 27- 36.
Daniel, P., Rodrigo, C., Mckeveer, T., Woodhead, M., Welham, S., & Lim, W. Time to first antibiotics and mortality adult hospitalized with community acquired pneumonia : a matched propensity analysis. Chest Clinic. 2015: 568-570.
Edis, E., Hatipoglu, O., Tansel, O., & Sut, N. Acinetobacter pneumonia: Is the outcome different from the pneumonia caused by other agents? Annals of Thoracic Medicine Vol. 5. 2010: 92-96.
Errlich, S., Quesenberry, C., Van den Eeden, S., Shan, J., & Ferara, A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes care. 2010: 55-60.
Exner, M., Bhattachary, S., Christiansen, B., Gebel, J., Goroncy-Bernes, P., Hartemann, P., et al. Antibiotic resistance: What is so special about multidrug- resistant Gram-negative bacteria? GMS Hyg Infect Control. 2017.
Gyssen, I., van den Broek, P., Kullberg, B., Hekster , Y., & van der Meer, J. Optimizing antimicrobial therapy. A method for antimicrobial use evaluation. J Antimicrob Chemother. 1992: 724-27.
International Diabetes Federation. Diabetic Atlas Sixth Edition; 2020
Kornum, J., Thomsen, R., Riis, A., & Lervang, H. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes care. 2007: 2251-55.
Lameshow, S. (1991). Sample Size Determination in Health Studies : A Practical Manual. Journal of The American Statistical Association, https://doi.org/10.2307/2290547.
Lepper , P., Ott, S., & Nuesch, E. Serum glucosa level for predicting death in patient admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ. 2012: 3397.
Liu, K., & Lee, G. C. Healthcare utilisation and cost expenditure for pneumonia in individuals with diabetes mellitus in the USA. Epidemiologi and Infection. 2019: 1-5.
Ljubic, S., Balachandran, A., Renar, I. P., Barada, A., & Metelko, Z. Pulmonary Infections In Diabetes Mellitus. Diabetologia Croatia. 2005: 115-124.
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bertlett, J. G., Campbell, G. D., Dean, N. C., et al. Infectious Disease Society of America/American Thoracic Society Consensus on the Management of Community Acquired Pneumonia in Adults. Clin Infect Dis. 2007: 27-72.
Ministry of Health Republic of Indonesia. Pedoman pelayanan kefarmasian untuk terapi antibiotik. Jakarta: 2011.
Perhimpunan Dokter Paru Indonesia (PDPI). Pneumonia Komuniti : Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta: PDPI; 2014
Polat, M., Ozdemir, M. N., Akyer, E., Uzunlulu, M., & Oguz, A. Pneumonia in Patients with Diabetes Mellitus: A Single-Center Experience. Eurasian Journal of Medicine and Oncology. 2017: 14-18.
Rumende, C. M., Chen, L. K., Karuniawati, A., Bratanata, J., Falasiva, R., Sitorus, T. P., et al. Hubungan Antara ketepatan Pemberian Antibiotik Berdasarkan Alur Gyssen dengan Perbaikan Klinis Pasien pada Pneumonia Komunitas. Jurnal Penyakit Dalam Indonesia. 2019: 71-77.
Saibal, M., Rahman, S., Nishat, L., Sikder, N., Begum, S., Islam, M., et al. Community acquired pneumonia in diabetic and non-diabetic hospitalized patients: presentation, causative pathogens and outcome. Bangladesh Med Res Coun Bull. 2012: 98-103.
Spencer, J., & Korbel, L. Diabetes melitus and infection: an evaluation of hospital utilisation and management cost in United States. J Diabetes Complicant. 2015:192-195.
Van den Borst, B., Gosker, H., Zeegers, M., & Schols, A. Pulmonary infection in diabetes: a metaanalysis. Chest. 2010: 393-406.
Yacovo, S. D., Garcia-Vidal, C., Viasus, D., Adamuz, J., Oriol, I., Gili, F., et al. Clinical Features, Etiology, and Outcomes of Community-Acquired Pneumonia in Patients with Diabetes Mellitus. Medicine. 2013: 42-50.
